Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in other blood cancers and transplant
- New trial
Other blood cancers and transplant
Phase I Daratumumab (CD38) Immunotherapy in High-Risk T-ALL/T-LLy
New York Medical College is sponsoring a Phase I trial to assess the safety of daratumumab—a CD38-directed monoclonal antibody—administered after TBI-based myeloablative conditioning and allogeneic HCT in children,…
NCT04972942 - New trial
Other blood cancers and transplant
Phase 2 Study of Blinatumomab (CD19 Targeted) and Venetoclax (BCL2 Inhibitor) in KMT2A-Altered Infant ALL
This trial evaluates the safety and efficacy of adding CD19-directed blinatumomab and BCL2 inhibitor venetoclax to standard chemotherapy in infants with newly diagnosed ALL with either KMT2A rearrangement or…
NCT06317662 - New trial
Other blood cancers and transplant
Phase II Study of IM-TMI in High-Risk Hematologic Malignancies
This trial by UIC is evaluating the addition of intensity-modulated total marrow irradiation (9Gy) to standard FluBu4 conditioning and post-transplant cyclophosphamide for high-risk AML, CML, and MDS patients…
NCT06802315 - New trial
Other blood cancers and transplant
Phase I Study of Ruxolitinib Plus Abemaciclib for Patients With Primary or Post-PV/ET Myelofibrosis
Memorial Sloan Kettering is assessing the safety and efficacy of combining ruxolitinib (a JAK1 inhibitor) with abemaciclib (a CDK4/6 inhibitor) in patients with primary or post-polycythemia vera/essential…
NCT05714072 - Trial result
Other blood cancers and transplant
High-Dose Palifermin Shows Promise in Preventing Acute GVHD Following Unrelated Donor HCT
In this phase 1/2 trial of 31 patients undergoing reduced-intensity conditioning with HLA-matched unrelated donor peripheral-blood hematopoietic cell transplantation (HCT), palifermin was administered in escalating…
- New trial
Other blood cancers and transplant
Frontline Ziftomenib in NPM1-Mutated or KMT2A-Rearranged AML
Ohio State University is investigating whether ziftomenib, a menin-MLL inhibitor taken daily in 28-day cycles, can effectively treat patients with NPM1-mutated or KMT2A-rearranged AML who are not eligible for…
NCT06930352 - New trial
Other blood cancers and transplant
Phase I Study: BAFF CAR-T Cells (LMY-920) in Relapsed/Refractory CLL
Cleveland Clinic is investigating BAFF-ligand CAR T cells (LMY-920) following B-cell depletion with obinutuzumab, along with cyclophosphamide and fludarabine, in heavily pre-treated CLL patients to overcome…
NCT06916767 - New trial
Other blood cancers and transplant
Sequential Decitabine with FLAG-Ida and RIC HCT for High-Risk Myeloid Malignancies
Fred Hutchinson Cancer Center is evaluating a sequential regimen that combines decitabine with FLAG-Ida chemotherapy and reduced-intensity conditioning using total body irradiation, followed immediately by an…
NCT06928662 - New trial
Other blood cancers and transplant
Phase 1 Study: Allogeneic Anti-CD7 CAR-T (BEAM-201) in Relapsed/Refractory T-ALL/T-LLy
Children's Hospital of Philadelphia is evaluating BEAM-201, an allogeneic anti-CD7 CAR-T cell therapy, to determine its safety, tolerability, and preliminary efficacy in patients with relapsed/refractory T-cell acute…
NCT06934382 - New trial
Other blood cancers and transplant
Phase 1 Study: STX-0712 in Advanced Hematologic Malignancies
Solu Therapeutics, Inc is conducting a first-in-human, open‐label trial evaluating STX-0712 in patients with advanced CMML and AML who have exhausted available treatment options. Using a dose escalation and expansion…
NCT06950034 - New trial
Other blood cancers and transplant
Phase 1/1b Study of CER-1236 in Relapsed/Refractory AML and TP53-mutated or MRD-Positive Disease
CERo Therapeutics Holdings, Inc. is evaluating CER-1236—an autologous chimeric engulfment receptor T-cell therapy—in a first-in-human, open-label phase 1/1b study for patients with relapsed/refractory AML, including…
NCT06834282 - Trial result
Other blood cancers and transplant
INCB057643 Rebalances Bone Marrow in MPNs by Shifting Megakaryopoiesis Toward Erythropoiesis
Preclinical data using a patient-derived xenograft model and clinical analyses from MPN patients treated with INCB057643 demonstrated that this BET inhibitor reduces JAK2 V617F+ stem cells and dysplastic…
- Trial result
Other blood cancers and transplant
TP-0903 Shows Early Signs of Activity in Heavily Pretreated FLT3-ITD AML Patients
In a phase 1b/2 trial, three relapsed/refractory AML patients with FLT3-ITD mutations were treated with oral TP-0903, starting at 50 mg daily—with dose reduction to 37 mg for one patient due to manageable grade 3…
- Trial result
Other blood cancers and transplant
Novel Immunotherapy Combo Yields High Response Rates in Non-Fit Frontline AML Patients
In the AARON phase I/II trial, frontline non-fit AML patients with adverse risk profiles treated with azacitidine/venetoclax plus dual checkpoint blockade using nivolumab (anti-PD-1) and relatlimab (anti-LAG-3)…
- Trial result
Other blood cancers and transplant
SENTI-202’s Dual-Targeting CAR NK Cell Therapy Shows Promising AML Activity and Hematopoietic Recovery
In a Phase I study of relapsed/refractory AML, SENTI-202—a logic gated CAR NK cell therapy targeting both CD33 and FLT3 while sparing EMCN+ healthy HSPCs—demonstrated marked blast reduction with MRD-negative complete…
- New trial
Other blood cancers and transplant
TCR α/β Depleted PBSC Transplantation in Inherited Bone Marrow Failure Disorders
This phase II trial at the Masonic Cancer Center investigates T cell receptor α/β depletion in PBSC transplantation for patients with inherited bone marrow failure syndromes, aiming to eliminate routine GVHD…
NCT03579875 - New trial
Other blood cancers and transplant
Phase II MeziKD Combines Novel Agents in Relapsed/Refractory MM with Extramedullary Disease
Roswell Park Cancer Institute is evaluating a regimen of mezigdomide, carfilzomib, and dexamethasone to target relapsed/refractory multiple myeloma with extramedullary disease. This trial leverages a cereblon…
NCT06627751 - New trial
Other blood cancers and transplant
Phase II Dasatinib & Quercetin with CAR-T Therapy in Advanced Multiple Myeloma
Mayo Clinic is investigating a regimen combining dasatinib and quercetin with preconditioning chemotherapy and CAR-T cell therapy for patients with relapsed/refractory multiple myeloma on fourth-line treatment and…
NCT06940297 - New trial
Other blood cancers and transplant
First-in-Human Phase I Study of SAR446523 in Relapsed/Refractory Multiple Myeloma
Sanofi is assessing subcutaneous SAR446523, an anti-GPRC5D ADCC-enhanced monoclonal antibody, in a first-in-human study of heavily pretreated MM patients. The trial will determine the safety profile,…
NCT06630806 - New trial
Other blood cancers and transplant
Phase I Master Protocol Evaluates BCMA-Directed CAR-T Therapies in R/R MM
Kite, a Gilead Company, is running a proof-of-concept master protocol to assess BCMA-specific CAR-T cell therapies—featuring an alternative binding domain—in patients with relapsed/refractory multiple myeloma, with…
NCT04155749 - New trial
Other blood cancers and transplant
Phase 1b/2a Study Evaluates SNIPR001 with Levofloxacin in HSCT Patients Harboring FQR E. coli
SNIPR Biome Aps. is investigating the safety, PK/PD, and preliminary efficacy of SNIPR001 administered with standard levofloxacin in allogeneic HSCT recipients colonized with fluoroquinolone-resistant E. coli. This…
NCT06938867 - New trial
Other blood cancers and transplant
Phase 1/2 Study of Tuspetinib (HM43239) in AML, MDS, and CMML
Aptose Biosciences Inc. is exploring the safety, tolerability, and optimal dosing of tuspetinib—with or without venetoclax (±azacitidine)—in patients with relapsed/refractory AML, MDS-IB2, CMML, and newly diagnosed…
NCT03850574 - New trial
Other blood cancers and transplant
Phase I Post-Transplant Maintenance with Tagraxofusp in CD123+ Myeloid Disorders
The University of Virginia is investigating escalating doses of tagraxofusp—a diphtheria toxin-IL3 fusion protein—as maintenance therapy post-allogeneic HCT in patients with CD123+ AML, CMML, and myelofibrosis.…
NCT05233618 - New trial
Other blood cancers and transplant
Phase II MyeloMATCH Trial Examines ASTX727 ± Enasidenib in Higher-Risk IDH2-Mutated MDS
The National Cancer Institute is comparing cedazuridine-decitabine (ASTX727) alone versus its combination with enasidenib in treatment-naïve, higher-risk IDH2-mutated MDS patients. This study evaluates whether adding…
NCT06577441 - New trial
Other blood cancers and transplant
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics is assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AUTX-703 in a multicenter dose escalation and optimization trial for patients with relapsed/refractory AML and…
NCT06846606 - New trial
Other blood cancers and transplant
Phase Ib/II Venetoclax Plus Vincristine in Relapsed/Refractory Lymphoid Malignancies
ECOG-ACRIN is investigating the safety, tolerability, and efficacy of combining venetoclax with either liposomal or sulfate vincristine in patients with relapsed/refractory acute lymphoblastic leukemia and…
NCT03504644 - New trial
Other blood cancers and transplant
Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
Eli Lilly’s master protocol is designed to assess the long-term safety and efficacy of pirtobrutinib in participants from prior originator studies. This framework, using individual study-specific appendices, enables…
NCT06876649
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.